欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (7): 829-834.doi: 10.12092/j.issn.1009-2501.2020.07.017

• 综述与讲座 • 上一篇    下一篇

肠道菌群在心血管疾病及治疗中的研究进展

阎雨1,刘康2,连雯雯1,张臻1,赫军1   

  1. 1中日友好医院,北京 100029;2国家电网公司北京电力医院,北京 100073
  • 收稿日期:2020-04-08 修回日期:2020-05-28 出版日期:2020-07-26 发布日期:2020-07-31
  • 作者简介:阎雨,女,博士,药师,研究方向:心血管药理学与新药发现。 E-mail: yy_imm@126.com
  • 基金资助:
    北京市自然科学基金资助项目(7204303);中日友好医院院级科研基金(2018-1-QN-15)

Research progress on roles of gut microbiota in cardiovascular disease and treatment

YAN Yu 1, LIU Kang 2, LIAN Wenwen 1, ZHANG Zhen 1, HE Jun 1   

  1. 1 China-Japan Friendship Hospital, Beijing 100029, China; 2 Electric Power Teaching Hospital, Capital Medical University, Beijing 100073, China
  • Received:2020-04-08 Revised:2020-05-28 Online:2020-07-26 Published:2020-07-31
  • Contact: 赫军,男,博士,副主任药师,研究方向:中药活性成分的发现和新药开发。 Tel: 15010297582 E-mail: 15010297582@126.com

摘要: 心血管疾病(CVD)是一种严重危害人类健康的慢性疾病,位居全球患病率和死亡率首位。在人类肠道聚集了细菌、病毒等组成的群落,连同它们的基因组一起被称为肠道菌群。近年来,研究表明肠道菌群通过产生和释放氧化三甲胺、胆汁酸和短链脂肪酸等重要代谢物,影响宿主的各种代谢途径,在动脉粥样硬化、高血压、心肌梗死、心力衰竭、血脂异常等多种CVD中发挥重要作用。膳食干预、粪便移植、小分子微生物酶抑制疗法等基于肠道菌群的个体化治疗方案可能为CVD提供新的治疗策略。

关键词: 心血管疾病, 肠道菌群, 个体化治疗, 治疗策略

Abstract: Cardiovascular disease (CVD), a chronic disease endangering human health, remains the highest morbidity and mortality globally. The human gut is inhabited by communities of bacteria and viruses, along with their genome, are collectively known as the gut microbiota. Recent reserch suggests that gut microbiota affects various metabolic pathways in the host by producing and releasing important metabolites such as trimethylamine oxide, bile acids and short chain fatty acids, and play an important role in pathologies of CVD, such as atherosclerosis, hypertension, myocardial infarction, heart failure and dyslipidemia. Individual treatment based on gut microbiota, including diet intervention, fecal microbiota transplantation and small molecule antimicrobial enzyme therapeutics, may provide a potential novel strategy for therapeutics.

Key words: cardiovascular disease, gut microbiota, individual treatment, therapeutic strategy

中图分类号: